Ureteral Calculi Clinical Trial
— 3Official title:
A Multicenter, Prospective, Randomized, Controlled Clinical Study of Ningmitai Capsule to Promote the Passage of Residual Fragments After Ureteroscopic Lithotripsy
Verified date | October 2023 |
Source | Xintian Pharmaceutical |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Objective: To observe the effect of Ningmitai capsule on ureteral calculi after lithotripsy and evaluate the safety of treatment. Study Design: A multicenter, prospective, randomized, controlled clinical study design was adopted Interventions: control group: Give antibiotics or diclofenac sodium suppository as needed. Ningmitai group: Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day. combination group (Ningmitai plus tamsulosin).: Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group.
Status | Completed |
Enrollment | 251 |
Est. completion date | April 25, 2019 |
Est. primary completion date | April 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Diagnosed as upper urinary calculi by B-ultrasound, kidney and upper bladder (KUB), intravenous urogram (IVU) or computerized tomography (CT) before surgery with the ages between 20 and 70 years. 2. Having ureteral residual fragments post URL and the diameter more than 5mm. 3. The lithotripsy went smoothly with expected outcomes and without any ureteral perforation, mucous exfoliation, kidney or bladder injury, serious bleeding or any other complications. 4. Willing and able to participate in this study and comply with all scheduled visits, treatment plans and complete the clinical observations. Exclusion Criteria: 1. Pregnancy, severe diabetes, or renal insufficiency. 2. Ureteral stricture and lower urinary tract obstruction. 3. Concomitant treatment with a1-receptor antagonists, or Chinese traditional medicines who can be used to relieve stranguria and expel stone, or any other treatment that might interference the efficacy evaluation. 4. Unwilling or unable to comply with the administration regimen described in the protocol, or having an incomplete profile, hence their efficacy and safety couldn't be evaluated. 5. Severe adverse events and need to withdraw from the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Xintian Pharmaceutical |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the stone expulsion time, stone-free time | The diminishing or vanishing of residual fragment identified by post-surgery B-ultrasound or KUB could suggest a residual fragment expulsion. Evaluation with KUB showing the shadow of calculi disappearing completely followed by a confirmation using CT could suggest a residual fragment clearance. | From baseline to 12 weeks of treatment | |
Secondary | the stone expulsion rate and stone-free rate. | The diminishing or vanishing of residual fragment identified by post-surgery B-ultrasound or KUB could suggest a residual fragment expulsion. Evaluation with KUB showing the shadow of calculi disappearing completely followed by a confirmation using CT could suggest a residual fragment clearance. | From baseline to 12 weeks of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05100017 -
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
|
N/A | |
Recruiting |
NCT03692715 -
Antibiotic Prophylaxis Before Shock Wave Lithotripsy
|
Phase 4 | |
Recruiting |
NCT01450566 -
Intraureteral Lidocaine for Post-Ureteroscopy Pain
|
N/A | |
Completed |
NCT00831701 -
Medical Expulsive Therapy of Single Distal Ureteral Stones
|
N/A | |
Completed |
NCT00177086 -
Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi
|
Phase 3 | |
Completed |
NCT02577146 -
The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic
|
N/A | |
Completed |
NCT00517205 -
Study on 'The Use of Non-contrast Helical Computerized Tomogram in Predicting Treatment Outcomes of Upper Ureteric Stone by Extracorporeal Shock Wave Lithotripsy Using the Sonolith 4000+ Lithotripter'
|
N/A | |
Completed |
NCT03888144 -
Study of Ketorolac Versus Opioid for Pain After Endoscopy
|
Phase 4 | |
Not yet recruiting |
NCT04606758 -
Fluoroscopic Guided vs US-guided Percutaneous Nephrolithotripsy for the Treatment of Stone Disease
|
N/A | |
Not yet recruiting |
NCT01008267 -
Shockwave Lithotripsy (SWL) Under Selective, General Anesthesia.
|
N/A | |
Completed |
NCT04069338 -
Comparison of Lithotripsy Urolithiasis Machines
|
N/A | |
Recruiting |
NCT04069013 -
Standard vs Mini-PCNL for the Treatment of Stone Disease
|
N/A | |
Withdrawn |
NCT00304317 -
Celecoxib (Celebrex) in the Management of Acute Renal Colic
|
Phase 4 | |
Recruiting |
NCT01167062 -
Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones
|
Phase 4 | |
Completed |
NCT01144949 -
Study of Silodosin to Facilitate Passage of Urinary Stones
|
Phase 2 | |
Terminated |
NCT03614052 -
Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy
|
Phase 4 | |
Completed |
NCT03344120 -
Symptoms Comparison: Suture-stent vs Conventional Double-J Stents After Ureterorenoscopy. A Prospective Randomized Trial
|
N/A | |
Completed |
NCT05153629 -
Noninvasive Electrical Stimulator as a Pain Control Treatment Post-ureteroscopy
|
N/A | |
Recruiting |
NCT05739812 -
The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery
|
N/A | |
Completed |
NCT01542593 -
Evaluating Ureteral Length Using Computed Tomography (CT)
|
N/A |